Thanks, Malcolm. Appreciate your knowledge and response. I guess we all agree that it's great to have someone like you on this forum! I mean it!
Will see my tx sensitivity early next week. Will have 3 weeks blood test coming Friday, incl. VL. They do VL at 3 weeks first because it takes a few days to get Incivek delivered here. So if your 4 weeks result is good (under 1000 or UND) you need to have the pills to hand. Pharmacies obviously do not have Incivek in stock (around USD 3600 for 42 pills). Cheers!
mallani said
Nov 13, 2012
Hi Bouba, alleles at IL28B may be CC, CT and TT. They were useful in predicting likely Interferon sensitivity, and therefore likelihood of response to SOC. If CC had a 60% chance, CT would have 40% chance and TT would have 30% chance ( give or take). There have been plenty of papers suggesting this ( polymorphism) is not as relevant in triple Rx. The Inter. sensitivity certainly is which is why I like the 4 week leadin before adding Vict. I am CT as well, but as I had a >2 log VL drop after 4 weeks, at least I know that I'm Inter. sensitive. Cheers.
Bouba said
Nov 13, 2012
Here in Europe, hepatologists say there will be no alternative to the current triple tx (with Inc or Vic) in the market at least till 2014... And then they look at Gilead as a frontrunner. There will be more coming between now and then but GS 7977 has a fat chnace to be approved first.
Malcolm, you mentioned CC allele... is that the one that responds best? I have CT and the lab said I could show a moderate response ... Thanks and cheers!
mallani said
Nov 13, 2012
Great result, Joe!
Jim, Gilead have to recoup some of the $11 billion they spent acquiring control of GS7977. It wouldn't surprise me if they just got approval for GS7977 + Peg + Riba just to sell some of the stuff! Joe's trial sounds good, but we are stuck with Peg and Riba. BTW-fish is a golden trevally from the Great Barrier Reef.
JoeV said
Nov 13, 2012
I'm participating in a phase 3 QUAD Rx clinical tria right nowl, which includes an NS5A replication inhibitor, protease inhibitor, Ribavirin and PegInterferon.
Today I received end of week 1 results and my viral load went from 1.4 million to 53 !!!!!
marktrux said
Nov 13, 2012
It is comming up on the end of the year, no better way to take care of the stockholders then to release some early phase preliminary results to boost profits. Most of current early phase tests have a very narrow field of candadites that are eligable. We really need more development on drugs usefull to broader range of persons. I understand that you can't hit a "home run" everytime, but a lot of these early test releases are purely profit motivated.
JIme said
Nov 13, 2012
It's all about the $. Nice fish btw.
mallani said
Nov 12, 2012
I think there is too much early reporting in the media, of each stage of the multiple trials of the multiple new drugs. I can understand the DrugCo's want to keep Hepatologists informed of progress. Really, do we care about a Phase 2 trial reporting 100% SVR 4? (Gilead). It might be good for the share price, but we want SVR12 or SVR24 results from Phase 3 trials. When you study results, look at exclusions to the trials. One trial would only take patients with the IL28B CC allele! Phase 2 trials may only have ~200 participants, wheras Phase 3 trials often have 3000. In the search for Interferon-free regimes, have a good look at some of these drugs. If used without Inter. the results are pretty poor! To combat the loss of Inter., the ideal Rx regime will probably be a Quad Rx., blocking NS3, NS5, a polymerase and Riba.
So GS-7977 is now Sofosbuvir- what a mouthful, but get used to it. It appears to be the frontrunner.
-- Edited by mallani on Tuesday 13th of November 2012 02:21:59 AM
Thanks, Malcolm. Appreciate your knowledge and response. I guess we all agree that it's great to have someone like you on this forum! I mean it!
Will see my tx sensitivity early next week. Will have 3 weeks blood test coming Friday, incl. VL. They do VL at 3 weeks first because it takes a few days to get Incivek delivered here. So if your 4 weeks result is good (under 1000 or UND) you need to have the pills to hand. Pharmacies obviously do not have Incivek in stock (around USD 3600 for 42 pills). Cheers!
Hi Bouba, alleles at IL28B may be CC, CT and TT. They were useful in predicting likely Interferon sensitivity, and therefore likelihood of response to SOC. If CC had a 60% chance, CT would have 40% chance and TT would have 30% chance ( give or take). There have been plenty of papers suggesting this ( polymorphism) is not as relevant in triple Rx. The Inter. sensitivity certainly is which is why I like the 4 week leadin before adding Vict. I am CT as well, but as I had a >2 log VL drop after 4 weeks, at least I know that I'm Inter. sensitive. Cheers.
Here in Europe, hepatologists say there will be no alternative to the current triple tx (with Inc or Vic) in the market at least till 2014... And then they look at Gilead as a frontrunner. There will be more coming between now and then but GS 7977 has a fat chnace to be approved first.
Malcolm, you mentioned CC allele... is that the one that responds best? I have CT and the lab said I could show a moderate response ... Thanks and cheers!
Great result, Joe!
Jim, Gilead have to recoup some of the $11 billion they spent acquiring control of GS7977. It wouldn't surprise me if they just got approval for GS7977 + Peg + Riba just to sell some of the stuff! Joe's trial sounds good, but we are stuck with Peg and Riba. BTW-fish is a golden trevally from the Great Barrier Reef.
It is comming up on the end of the year, no better way to take care of the stockholders then to release some early phase preliminary results to boost profits. Most of current early phase tests have a very narrow field of candadites that are eligable. We really need more development on drugs usefull to broader range of persons. I understand that you can't hit a "home run" everytime, but a lot of these early test releases are purely profit motivated.
I think there is too much early reporting in the media, of each stage of the multiple trials of the multiple new drugs. I can understand the DrugCo's want to keep Hepatologists informed of progress. Really, do we care about a Phase 2 trial reporting 100% SVR 4? (Gilead). It might be good for the share price, but we want SVR12 or SVR24 results from Phase 3 trials. When you study results, look at exclusions to the trials. One trial would only take patients with the IL28B CC allele! Phase 2 trials may only have ~200 participants, wheras Phase 3 trials often have 3000. In the search for Interferon-free regimes, have a good look at some of these drugs. If used without Inter. the results are pretty poor! To combat the loss of Inter., the ideal Rx regime will probably be a Quad Rx., blocking NS3, NS5, a polymerase and Riba.
So GS-7977 is now Sofosbuvir- what a mouthful, but get used to it. It appears to be the frontrunner.
-- Edited by mallani on Tuesday 13th of November 2012 02:21:59 AM